NYSE:MDT
93.16
0.84
(0.91%)
Medtronic Inc
MDT-N
Analysis and Opinions about MDT-N
Signal
Opinion
Expert
HOLD
HOLD
April 20, 2020
It has grown its dividend 28 consecutive years. Not all of its businesses will be firing. It will not get the same lift because it is not 100% exposed to COVID-19. After COVID the whole diagnostic space will be an interesting one. The dividend is probably relatively safe.
Show full opinionHide full opinion
It has grown its dividend 28 consecutive years. Not all of its businesses will be firing. It will not get the same lift because it is not 100% exposed to COVID-19. After COVID the whole diagnostic space will be an interesting one. The dividend is probably relatively safe.
PAST TOP PICK
PAST TOP PICK
February 18, 2020
(A Top Pick Oct 02/19, Up 7%) They reported today and miss expectations. It's a big global company. There's global demand for their medical devices; in Asia, for instance, there's rising heart disease. So, Medtronic can fulfill this demand.
Show full opinionHide full opinion(A Top Pick Oct 02/19, Up 7%) They reported today and miss expectations. It's a big global company. There's global demand for their medical devices; in Asia, for instance, there's rising heart disease. So, Medtronic can fulfill this demand.
BUY
BUY
January 17, 2020
A large cap diversified company. Their recent acquisition to get into the robotic spine is positive. It has everything for tools and devices, including pacemakers. The chart looks great. This would be the one to own in the space.
Show full opinionHide full opinionA large cap diversified company. Their recent acquisition to get into the robotic spine is positive. It has everything for tools and devices, including pacemakers. The chart looks great. This would be the one to own in the space.
BUY
BUY
October 17, 2019
Good company. Biggest product is pacemakers. Trades at 19x earnings. Good stock price stability. Trades attractively against peers. Given the multiple, and predictability of earnings, you should look at a 10% return or greater over time.
Show full opinionHide full opinionGood company. Biggest product is pacemakers. Trades at 19x earnings. Good stock price stability. Trades attractively against peers. Given the multiple, and predictability of earnings, you should look at a 10% return or greater over time.
TOP PICK
TOP PICK
October 2, 2019
They built the first pacemaker and have gone on to make several similar devices. They have gone global. Places like India need these devices for heart disease, for example. The CEO is from Bangladesh and understands this vast market. They are moving from selling the device to improving people's health. If they succeed, they will be hugely profitable. (Analysts’ price target is $116.38)
Show full opinionHide full opinionThey built the first pacemaker and have gone on to make several similar devices. They have gone global. Places like India need these devices for heart disease, for example. The CEO is from Bangladesh and understands this vast market. They are moving from selling the device to improving people's health. If they succeed, they will be hugely profitable. (Analysts’ price target is $116.38)
BUY
BUY
September 6, 2019
The stock couldn’t look any better. An absolute buy and hold. It took a long time to break through $100 but they’ve done it. Would be a buyer here.
Show full opinionHide full opinionThe stock couldn’t look any better. An absolute buy and hold. It took a long time to break through $100 but they’ve done it. Would be a buyer here.
HOLD
HOLD
May 3, 2019
Don't sell it just to go into a Merck. Add to your diversity instead by buying a basket. Likes Medtronic. Diversified. Into robotic surgery. 8% EPS growth. Relatively inexpensive. Very large, so you don't get the same growth as smaller companies.
Show full opinionHide full opinionDon't sell it just to go into a Merck. Add to your diversity instead by buying a basket. Likes Medtronic. Diversified. Into robotic surgery. 8% EPS growth. Relatively inexpensive. Very large, so you don't get the same growth as smaller companies.
BUY
BUY
December 3, 2018
Likes it very much. Thought bought Covidien, a medical device maker, a few years back. They're executing very well, such as their diabetes franchise which boosted their guidance recently to 5.5% growth in 2019. Valuation good at 17.5x vs. peers. Many of their products are essential services which is anothe tailwind.
Show full opinionHide full opinionLikes it very much. Thought bought Covidien, a medical device maker, a few years back. They're executing very well, such as their diabetes franchise which boosted their guidance recently to 5.5% growth in 2019. Valuation good at 17.5x vs. peers. Many of their products are essential services which is anothe tailwind.
PAST TOP PICK
PAST TOP PICK
September 18, 2018
(A Top Pick November 13, 2017. Up 24%). He owned this as a diversified play on the medical device market. He sold the stock when it reached $90 and used the proceeds to buy Boston Scientific instead.
(A Top Pick November 13, 2017. Up 24%). He owned this as a diversified play on the medical device market. He sold the stock when it reached $90 and used the proceeds to buy Boston Scientific instead.
WEAK BUY
WEAK BUY
May 9, 2018
He likes medical device manufacturers. It seems they are taking market share in a booming market. They are well diversified. The company continues to put up great numbers.
He likes medical device manufacturers. It seems they are taking market share in a booming market. They are well diversified. The company continues to put up great numbers.
BUY
BUY
March 21, 2018
Likes this. One of the most dominant medtech companies, diversified from hips and knees to cardio. Good 15x forward earnings and a stable dividend yield. It's an economy of scale game in medtech, and MDT is well-positioned. Great
balance sheet and growth profile.
Likes this. One of the most dominant medtech companies, diversified from hips and knees to cardio. Good 15x forward earnings and a stable dividend yield. It's an economy of scale game in medtech, and MDT is well-positioned. Great
balance sheet and growth profile.
COMMENT
COMMENT
January 31, 2018
A dividend aristocrat, gradually increasing the dividend every year. They are in medical devices. Any increase in surgery, hospital time and heart disease would be an upside for this story. It’s been a relative laggard for the group, but has been a very good performer longer-term, and has rewarded shareholders very well. Sees this as a mutual fund of device companies.
A dividend aristocrat, gradually increasing the dividend every year. They are in medical devices. Any increase in surgery, hospital time and heart disease would be an upside for this story. It’s been a relative laggard for the group, but has been a very good performer longer-term, and has rewarded shareholders very well. Sees this as a mutual fund of device companies.
HOLD
HOLD
January 11, 2018
Medical devices. A good global name. He has been bullish on medical devices for quite some time. He has shifted that down recently because it was getting close to his break points. Earnings were ratcheted down because of hurricane noise because of Puerto Rican noise. IHI-N is the US ETF he would use to take positions in this sector. You want to get through this next quarter. You have good metrics.
Medical devices. A good global name. He has been bullish on medical devices for quite some time. He has shifted that down recently because it was getting close to his break points. Earnings were ratcheted down because of hurricane noise because of Puerto Rican noise. IHI-N is the US ETF he would use to take positions in this sector. You want to get through this next quarter. You have good metrics.
TOP PICK
TOP PICK
November 13, 2017
This does stuff mainly related to cardiovascular, diabetes, spinal implants and a lot of neurology stuff. The stock has been bouncing between $90 and $75. Has 4%-5% earnings growth. Dividend yield of 2.3%. (Analysts’ price target is $90.)
This does stuff mainly related to cardiovascular, diabetes, spinal implants and a lot of neurology stuff. The stock has been bouncing between $90 and $75. Has 4%-5% earnings growth. Dividend yield of 2.3%. (Analysts’ price target is $90.)
COMMENT
COMMENT
October 13, 2017
This has certainly had its good days. It’s been quite a good company for many years. He likes the medical technology space.
This has certainly had its good days. It’s been quite a good company for many years. He likes the medical technology space.
Medtronic Inc(MDT-N) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 4
Neutral - Hold Signals / Votes : 1
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 5
Medtronic Inc(MDT-N) Frequently Asked Questions
What is Medtronic Inc stock symbol?
Medtronic Inc is a American stock, trading under the symbol MDT-N on the New York Stock Exchange (MDT). It is usually referred to as NYSE:MDT or MDT-N
Is Medtronic Inc a buy or a sell?
In the last year, 5 stock analysts published opinions about MDT-N. 4 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is HOLD. Read the latest stock experts' ratings for Medtronic Inc.
Is Medtronic Inc a good investment or a top pick?
Medtronic Inc was recommended as a Top Pick by Darren Sissons on 2020-04-20. Read the latest stock experts ratings for Medtronic Inc.
Why is Medtronic Inc stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Medtronic Inc worth watching?
5 stock analysts on Stockchase covered Medtronic Inc In the last year. It is a trending stock that is worth watching.
What is Medtronic Inc stock price?
On 2020-07-02, Medtronic Inc (MDT-N) stock closed at a price of $93.16.
